1. Home
  2. COCP vs QNCX Comparison

COCP vs QNCX Comparison

Compare COCP & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cocrystal Pharma Inc.

COCP

Cocrystal Pharma Inc.

HOLD

Current Price

$1.10

Market Cap

21.6M

Sector

Health Care

ML Signal

HOLD

Logo Quince Therapeutics Inc.

QNCX

Quince Therapeutics Inc.

HOLD

Current Price

$33.75

Market Cap

17.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COCP
QNCX
Founded
2006
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.6M
17.5M
IPO Year
2011
2019

Fundamental Metrics

Financial Performance
Metric
COCP
QNCX
Price
$1.10
$33.75
Analyst Decision
Strong Buy
Hold
Analyst Count
1
2
Target Price
$6.00
N/A
AVG Volume (30 Days)
70.7K
24.5K
Earning Date
05-15-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
54.65
N/A
EPS
N/A
N/A
Revenue
$12,712,091.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.76
$0.08
52 Week High
$2.03
$35.41

Technical Indicators

Market Signals
Indicator
COCP
QNCX
Relative Strength Index (RSI) 63.60 61.57
Support Level $0.90 $0.82
Resistance Level $1.22 $35.41
Average True Range (ATR) 0.07 2.46
MACD 0.00 -0.79
Stochastic Oscillator 60.58 34.79

Price Performance

Historical Comparison
COCP
QNCX

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.

Share on Social Networks: